>16 July: CordenPharma Invests €900m in Transformational Peptide Platform Expansion. Read Press Release: https://lnkd.in/enqc-t8b We are pleased to announce a record investment of ~€900m over the next 3 years in expanding our peptide platform, both at our Colorado, US site and in Europe. The expansions, covering both existing facilities and new constructions, will meet the pharmaceutical industry’s most stringent quality and technical standards for short and long peptide manufacturing, including BLA requirements. Our CordenPharma Colorado, US site expansion involves the planned construction of a new large-scale peptide manufacturing facility, and an additional increase in manufacturing trains in the existing facility. This is the result of rapidly increasing demand in the Diabetes and Obesity Glucagon-like Peptide 1 (GLP-1) agonist medications market, and comes off the back of multiple, long-term, multiyear contracts totaling ~€3bn, with potential upsides. The European expansion centers on the construction of a new state-of-the-art greenfield facility, with the aim of creating additional Peptide capacity to serve customers from initial early clinical to late-stage commercial manufacturing. These major expansion plans will act as the driving force behind our €1bn sales target for our Peptide Platform by 2028, reinforcing CordenPharma as a market leader in the integrated supply of small to large-scale services from APIs to Drug Products (for both Injectable and Oral Peptides). Dr. Michael Quirmbach, President & CEO of the CordenPharma Group comments: “These investments will profoundly strengthen our ability to provide valuable and much needed support to innovators for the benefit of patients. We are honored by the trust our customers have placed in us to deliver expert outsourcing for large multiyear contracts.” Dr. Signe Michel, Managing Director at Astorg comments: “We are proud of what Michael and the CordenPharma team have achieved through their striving for operational excellence, customer service and ambitious growth. We are excited about the opportunities ahead and to further strengthen the company’s peptide offering across the full drug lifecycle and value chain.” Judith Charpentier, Co-Head Flagship Fund and Head of Healthcare at Astorg comments: “CordenPharma has a unique opportunity to reinforce its leadership position in peptides with unmatched capacity and performance in large scale manufacturing. With the company’s proven track record and our investor experience in pharmaceutical services, we feel confident that our latest commitment will help the company seize this opportunity.” #CordenPharma #cdmo #peptides #GLP1s #diabetes #obesity #peptideagonists #oralpeptides #injectables #pharmamanufacturing #pharmaceuticals
Corden Pharma - A Full-Service CDMO
Arzneimittelherstellung
Basel, BS 35.420 Follower:innen
The partner you need.
Info
CordenPharma is your full-service partner in the Contract Development & Manufacturing (CDMO) of APIs, Lipid Excipients, Drug Products and Packaging. Through a network of cGMP facilities across Europe and the US organized under six technology platforms – Peptides, Lipids & Carbohydrates, Oligonucleotides, Injectables, Highly Potent & Oncology, Small Molecules - CordenPharma experts translate complex ideas, processes and projects at any stage of development into high-value pharmaceutical products. Visit to learn more > cordenpharma.com
- Website
-
https://www.cordenpharma.com
Externer Link zu Corden Pharma - A Full-Service CDMO
- Branche
- Arzneimittelherstellung
- Größe
- 1.001–5.000 Beschäftigte
- Hauptsitz
- Basel, BS
- Art
- Privatunternehmen
- Gegründet
- 2006
- Spezialgebiete
- Contract Development & Manufacturing Organization (CDMO), Sterile Injectable Drug Products, Aseptic Fill & Finish, Oligonucleotides, Lipid Excipients, LNP Formulation, Peptides, LNP Formulation, Highly Potent APIs & Drug Products und Small Molecule Drug Dosage Forms
Orte
Beschäftigte von Corden Pharma - A Full-Service CDMO
Updates
-
We would like to welcome, Christian Merz, Managing Director, CordenPharma Plankstadt, to the CordenPharma team! #cordenpharma #cdmo #leadership #drugproducts #pharmamanufacturing #pharmaceuticals
-
-
Attending the PDA/FDA Joint Regulatory Conference 2024 in Washington? Visit us at booth 310! Our team will be there to discuss our bespoke end-to-end solutions, covering all stages from drug development to commercialization. #cordenpharma #pdafda #cdmo #pharma #pharmaceuticals #pharmaindustry #drugdevelopment
-
-
We would like to welcome Michael Landau, Managing Director, CordenPharma Colorado, to the CordenPharma team! #cordenpharma #colorado #cdmo #leadership #apis #pharmaceuticals #pharmamanufacturing #peptides #hpapis
-
-
Visit us at ChemOutsourcing from September 3rd to 6th! Our team will be at booth #45, ready to answer all your questions about how we can support your drug development lifecycle at all stages, from sourcing of raw materials to secure your supply chain, through preclinical & commercial development and manufacturing of GMP starting materials, APIs, Lipid excipients, Lipid NanoParticles (LNPs), finished dosage drug products, Packaging and final distribution. #cordenpharma #chemoutsourcing2024 #cdmo #pharma #pharmaceuticals #drugdevelopment #drugproduct #apis
-
-
Join us at the Peptides Therapeutics Forum in Basel on August 22nd and 23rd - booth number 1 Don't miss out our poster presentation titled 'Flow – SPPS towards greener and more efficient peptide manufacturing' by Senior Scientist Oliver Kracker. #cordenpharma #cdmo #peptides #pharmaceuticals #pharmaindustry #drugdevelopment
-
-
> CordenPharma Lisbon (PT) inaugurates a new oral solid dosage tablet coating equipment upgrade in Manufacturing Unit 1! On 30th of July, CEO Dr. Michael Quirmbach and Chief Commercial Officer Dr. Stephan Haitz joined CordenPharma Lisbon Site Managing Director Rosário Fonseca, HR & Legal Director Isilda Serra, Production Director Margarida D. Henriques Henriques, Maintenance & Engineering Lead Vasco Dias, along with Site Project Teams and Unit Operators to hold an inauguration ceremony. This new cutting-edge coating equipment (Hütllin, Sepion 250) allows the Lisbon site to manufacture coated tablets, in addition to the uncoated tablets previously offered. Driven by our strategic decision to address the market demand and customer preference for coated tablets, the benefits of the new capability include important characteristics such as controlled release, taste masking, and greater protection of the Active Pharmaceuticals Ingredients (APIs) they contain. The installation and qualification of CordenPharma Lisbon’s new coating equipment took place in June 2024 and will go live in August 2024. CEO Michael Quirmbach kicked off the ceremony with a brief speech on the significance of the equipment upgrade, both in terms of its benefits to our customers, and in strengthening CordenPharma’s overall integrated offerings. He commented on the hard work by site Leaders, Project Teams and Operators involved in bringing this important project to reality, and the future opportunities that it drives for CordenPharma. The highlight of the inauguration was a ribbon cutting, followed by a delicious lunch buffet, allowing a well-deserved moment for all employees involved to celebrate this important technological upgrade for the Lisbon site. #CordenPharmaLisbon #tablets #coatedtablets #oralsoliddose #pharmaceuticals #drugproducts #pharmamanufacturing #controlledrelease #tastemasking #cdmo
-
-
Mimoun Ayoub, Ph.D., Sr. VP of Sales and Key Account Management, gives a video update at Tides US 2024 on key trends in the Tides CDMO space, and how CordenPharma is addressing them with the supply of complex modalities, such as peptides, lipids, and oligonucleotides, and integrated services like GMP Lipid NanoParticle Formulation, LNP Starter Kits and clinical to commercial supply of sterile injectable Drug Products. #cordenpharma #cdmo #tides #peptides #lipids #oligonucleotides #injectables #lnps #drugdevelopment #pharma #pharmaceuticals
-
Learn more about our LNP Manufacturing Services. Our new cGMP Lipid NanoParticle (LNP) manufacturing facility in Caponago, Italy, is FDA and EMA approved. Building on decades of sterile injectable experience, it fully supplements our existing LNP development capabilities. The 900 m² suite is state-of-the-art, Grade C throughout, fully scalable, and offers process and purification scale-up, including the following technologies and services: -A full variety of nanoparticle assembly systems, notably Impingement Jets Mixing (IJM) by Knauer and NxGen Microfluidic technology by Cytiva -A wide selection of purification technologies such as Ultrafiltration (UF), Diafiltration (DF) and Tangential Flow Filtration (TFF) - Comprehensive analytical services As part of our fully-integrated offering CordenPharma additionally offers Aseptic Fill & Finish services conveniently located under the same roof, as well as a wide selection of functional Lipid Excipients provided within the CordenPharma facility network. https://lnkd.in/d8EdQ_bf #CordenPhama #CDMO #LNP #lipidnanoparticles #pharmaceuticals #pharma #pharmaindustry #injectables
-
The Q2/24 edition of our newsletter Corden Connect is out today! Learn more about our new cGMP Lipid NanoParticle (LNP) manufacturing facility in Italy, the important role of crystallization processes, and our end-to-end Tides CDMO services & growth strategy in an interview with S. VP Mimoun Ayoub. https://lnkd.in/dgeX2-af Want to receive our latest news directly in your inbox? Sign up for our newsletter https://lnkd.in/d3vNGMPX #cordenpharma #cdmo #drugdevelopment #pharma #pharmaceuticals #pharmaindustry #lipidsnanoparticles #crystallization